Indapta Therapeutics is pioneering a novel approach to cancer treatment through its proprietary allogeneic natural killer (NK) cell therapy, specifically utilizing FcRγ-deficient NK cells, referred to as g-NK cells. These cells are derived from healthy donors and are designed to be an off-the-shelf solution, which means they can be administered without the need for patient-specific customization. The g-NK cells exhibit enhanced capabilities in targeting and destroying cancer cells, particularly when used in conjunction with FDA-approved monoclonal antibodies. This combination significantly improves the efficacy of existing immunotherapies, addressing the limitations of traditional autologous T-cell therapies.

The g-NK cell platform is characterized by its unique biological properties, including increased cytokine secretion, a favorable metabolic profile, and superior antibody-dependent cell-mediated cytotoxicity (ADCC) compared to conventional NK cells. Indapta has demonstrated the robust anti-cancer effects of g-NK cells in preclinical models, particularly in non-Hodgkin's lymphoma and multiple myeloma, showcasing their potential to enhance the effectiveness of treatments like rituximab and daratumumab. The company is advancing its g-NK cell therapy through clinical trials, aiming to provide a powerful new option for patients facing challenging cancer diagnoses.

United States

Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.

Indapta Therapeutics

Company Details